Search clinical trials for: Atezolizumab-Bevacizumab

Total 3015 results

Hospices Civils de Lyon

Recruiting

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST)

Gastric Adenocarcinoma | Metastatic Gastric Cancer | Advanced Gastric Carcinoma | Metastatic Adenocarcinoma

France
CHA University
Hoffmann-La Roche

Completed

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Advanced Hepatocellular Carcinoma

Korea, Republic of
CHA University

Recruiting

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy (HCC)

Hepatocellular Carcinoma

Korea, Republic of
Asan Medical Center
Seoul National University Hospital; Hanyang University; Soon Chun Hyang University

Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion (ALERT-HCC)

Hepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IV

Korea, Republic of
Sun Yat-sen University

Recruiting

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Hepatocellular Carcinoma

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Hepatocellular Carcinoma

United States
Samsung Medical Center

Recruiting

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Hepatocellular Carcinoma | Portal Vein Thrombosis

Korea, Republic of
University Hospital, Essen

Recruiting

Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer (COMBATBIL)

Biliary Tract Cancer

Spain, Germany
CHA University
Boryung Pharmaceutical Co., Ltd

Recruiting

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab (HCC)

Advanced Hepatocellular Carcinoma

Korea, Republic of
Abramson Cancer Center at Penn Medicine

Recruiting

SBRT With Atezo/Bev for HCC

Hepatocellular Carcinoma

United States
Replimune Inc.
Roche Pharma AG

Not yet recruiting

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recurrent Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma

United States, United Kingdom, France, Germany, Greece
Replimune Inc.
Roche Pharma AG

Active, not recruiting

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

MSS | pMMR | Refractory Metastatic Colorectal Cancer

United States
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
Fundación GECP

Active, not recruiting

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (TELMA)

Non Small Cell Lung Cancer

Spain
Medical University of Vienna

Recruiting

FMT in IT-refractory HCC - FAB-HCC Pilot Study

Hepatocellular Carcinoma

Austria
National Taiwan University Hospital

Active, not recruiting

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

NSCLC Stage IIIB~IV

Taiwan
University of Rochester

Withdrawn

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Cancer of Liver

United States
National Cancer Centre, Singapore
National University Hospital, Singapore; Singapore General Hospital; Tan Tock... and other collaborators

Recruiting

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (EMPHASIS)

Hepatocellular Carcinoma

Singapore
Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University; Fifth Affiliated Hospital, Sun Yat-Sen University; Second... and other collaborators

Not yet recruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Tumor Thrombus
Sun Yat-sen University

Completed

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Ludwig-Maximilians - University of Munich

Recruiting

Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (DEMAND)

Hepatocellular Carcinoma Non-resectable

Germany
Japanese Foundation for Cancer Research
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (AMBITION)

Breast Cancer

Japan
University of Texas Southwestern Medical Center
Genentech, Inc.

Recruiting

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST-B)

Hepatocellular Carcinoma

United States
National Cancer Centre, Singapore
Hoffmann-La Roche; Sirtex Medical; Singapore Clinical Research Institute

Recruiting

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients (STRATUM)

Locally Advanced Hepatocellular Carcinoma

Korea, Republic of, Singapore
Fudan University
Roche Pharma AG

Recruiting

Efficacy and Safety of T+A+RAD in HCC

Hepatocellular Carcinoma

China
University Hospital, Montpellier

Recruiting

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02)

Hepatocellular Carcinoma

France
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Shuhong Yi

Recruiting

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Recurrent Liver Cancer After Liver Transplantation

China
Zhongda Hospital

Not yet recruiting

Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study (CHANCE023)

HCC
Tae Won Kim

Recruiting

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab (DYNAMIC)

Hepatocellular Carcinoma

Korea, Republic of
Michael Dill
University of Cologne; German Cancer Research Center; Heidelberg University; Universitätsmedizin... and other collaborators

Not yet recruiting

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA)

Immunotherapy

Germany
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Recruiting

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)

Breast Cancer

France
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
University of Leicester
Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; British Lung Foundation and other collaborators

Active, not recruiting

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST)

Mesothelioma, Malignant

United Kingdom
Intergroupe Francophone de Cancerologie Thoracique
Roche Pharma AG; GFPC

Completed

Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC (CLINATEZO)

Small Cell Lung Cancer

France
Georgetown University
Genentech, Inc.

Recruiting

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Non-squamous Non-small-cell Lung Cancer

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center; Washington University School of Medicine; Merck... and other collaborators

Completed

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Malignant Glioma | Recurrent Glioblastoma

United States
Yonsei University

Not yet recruiting

Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer (SKYROCKET)

Non-small Cell Lung Cancer

Korea, Republic of
Fondazione Ricerca Traslazionale

Not yet recruiting

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT)

Non-small-cell Lung Cancer Patients

Italy
Yale University
Genentech, Inc.

Recruiting

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma

United States
ARCAGY/ GINECO GROUP
Hoffmann-La Roche

Active, not recruiting

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (ATALANTE)

Ovarian Cancer

Spain, Belgium, France, Germany, Austria, Czechia, Israel
National University Hospital, Singapore

Recruiting

Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma

Singapore
AGO Research GmbH
Hoffmann-La Roche

Active, not recruiting

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Recurrent Ovarian Carcinoma

Norway, Spain, France, Switzerland, Denmark, Germany, Sweden, Belgium, Finland, Austria, Estonia, Lithuania
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
Hoffmann-La Roche

Withdrawn

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Corvus Pharmaceuticals, Inc.
Genentech, Inc.

Completed

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Renal Cell Cancer | Metastatic Castration Resistant Prostate Cancer

United States, Canada, Australia
Incyte Corporation
Hoffmann-La Roche; Genentech, Inc.

Terminated

A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

UC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)

United States
First Affiliated Hospital of Zhejiang University
Hoffmann-La Roche; Geneplus-Beijing Co. Ltd.

Unknown

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Non-Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Completed

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States

Search clinical trials for: Atezolizumab-Bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations